Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10302323 | 1.00 | CNR2 (0.35) | CNR2HTR2AHTR2CHTR2BRIPK1 | |
| SCHEMBL11933177 | 0.95 | CTSL (0.41) | CNR2HTR2AHTR2CHTR2BRIPK1 | |
| SCHEMBL11933323 | 0.95 | CTSL (0.41) | CNR2HTR2AHTR2CHTR2BRIPK1 | |
| SCHEMBL12740608 | 0.94 | CNR2 (0.34) | CNR2HTR2AHTR2CHTR2BRIPK1 | |
| SCHEMBL10302318 | 0.94 | CNR2 (0.36) | CNR2HTR2AHTR2CHTR2BRIPK1 | |
| SCHEMBL12735744 | 0.94 | CNR2 (0.34) | CNR2HTR2AHTR2CHTR2BRIPK1 | |
| SCHEMBL10302311 | 0.94 | CNR2 (0.36) | CNR2HTR2AHTR2CHTR2BRIPK1 | |
| SCHEMBL10302319 | 0.93 | CNR2 (0.34) | CNR2HTR2AHTR2CHTR2BRIPK1 | |
| SCHEMBL12196874 | 0.92 | CTSL (0.39) | CNR2HTR2AHTR2CHTR2BCTSL | |
| SCHEMBL10301642 | 0.92 | CTSL (0.38) | CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435422-B2 | Five-ring compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-05-07 | — | — | US | disclosed |
| US-8435422-B2 | Five-ring compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20110240919-A1 | FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-10-06 | — | — | US | disclosed |
| US-20110240919-A1 | FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110240919-A1 | FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | NCAPD3, CCND3, ZKSCAN2 | CNR2 253/4885HTR2A 925/4885HTR2C 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.